Table 2.

Multivariate analysis for progression-free survival (PFS).

Variable	HR (95% CI)	p value
Gender		0.078
Male	1
Female	0.71 (0.49–1.04)
Stage		0.008
III	1
IV	2.02 (1.19–3.40)
Type of immunotherapy		0.042
Anti-PD1	0.70 (0.49–0.98)
Anti-PD-L1	1
Type of cancer		0.077
Lung cancer	1
Renal cancer	1.02 (0.67–1.52)
Bladder cancer	1.16 (0.76–1.74)
Ovarian cancer	0.49 (0.25–0.99)
Other	0.57 (0.30–1.05)
Endocrine complication		0.002
No	1
Yes	0.57 (0.39-0.81)
ECOG-PS		0.709
0–1	1
≥2	0.93 (0.63–1.37)